We plan to combine several orthogonal methods: Time-lapsed micro-CT imaging of mineralized 3D bioprinted bone organoids, mechanical property evaluations, clinical biomarker assays and next generation sequencing (NGS). The readouts from these measurements will be used to fit a machine learning model to a dataset of drug sensitivity and dosing generated within the proposed project. Finally, the model will be validated by an independent dataset of drug response in personalized OI organoids.